Oliver Zuehlke - Bayer Aktiengesellscha Insider

BAYRY -- USA Stock  

USD 21.69  0.81  3.60%

  Executive
Mr. Oliver Zuehlke was Independent Vice Chairman of the Supervisory Board, Employee Representative of Bayer Aktiengesellschaft since July 2015. He was Member of the Supervisory Board and Employee Representative at the Company from April 27, 2007. He is Member of the Presidial CommitteeMediation Committee, Audit Committee and Innovation Committee at the Company. He joined Bayer AG in Leverkusen, Germany, in 1985 and trained as a chemical production technician. During his training, in 1988, he became a member of the body representing young employees and apprentices. He chaired this body from 1990 to 1994. He was elected a fulltime member of the Works Council at the Leverkusen site in 1994 and was Deputy Chairman from 2002 to 2010. Since then, he has also been a member of the Economics Committee of Bayer AG. In 2009, he completed a distance learning course on human resources management. Between 2010 and 2015 he was Chairman of the Works Council at the Leverkusen site and also held various functions in the German Mining, Chemical and Power Workers Union . He was a member of the District Executive, the Regional Executive, the federal industrial group for the chemical industry, and the advisory board. From 2009 to 2015 Zuehlke was Chairman of the Bayer European Forum. In 2014 he became Member of the Supervisory Board of Bayer Pharma AG. Since 2015 he was Chairman of the Central Works Council of Bayer AG.
Age: 48  Executive Since 2015      
49 214 30 1  http://www.bayer.com
Zuehlke is Chairman of the Works Council of the Leverkusen site of Bayer AG and is Chairman of the Bayer European Forum. He is Member of the Supervisory Board at Bayer Pharma AG since May, 2014. He is Member of the Human Resources Committee at the Company.

Management Efficiency

The company has return on total asset (ROA) of 3.83 % which means that it generated profit of $3.83 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 8.38 % meaning that it generated $8.38 on every $100 dollars invested by stockholders.
The company has accumulated 60.73 B in total debt with debt to equity ratio (D/E) of 110.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Bayer Aktiengesellschaft has Current Ratio of 1.38 which is within standard range for the sector.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Steven BaertNovartis AG
2014
Felix EhratNovartis AG
2012
Sophie KornowskiBonnetRoche Holding AG
2012
Verena BrinerNovartis AG
2013
Karl MahlerRoche Holding AG
N/A
Silvia AyyoubiRoche Holding AG
2008
Jefrey PottAstraZeneca PLC
N/A
Katarina AgeborgAstraZeneca PLC
2011
Paul ArkelNovartis AG
2013
Adrian KempAstraZeneca PLC
2009
Victoria WhyteGlaxoSmithKline plc
2011
Urs JaisliRoche Holding AG
N/A
Cristina WilburRoche Holding AG
2016
William WintersNovartis AG
2013
Karenann TerrellGlaxoSmithKline plc
2017
Sophie KornowskiBonnetRoche Holding AG
2012
Thomas LarsenAstraZeneca PLC
2014
Stephan FeldhausRoche Holding AG
2010
Michele GalenNovartis AG
2012
David RedfernGlaxoSmithKline plc
2008
Jeffrey PottAstraZeneca PLC
2009

Entity Summary

Bayer Aktiengesellschaft operates as a life science company worldwide. The company was founded in 1863 and is headquartered in Leverkusen, Germany. Bayer Aktiengesellscha is traded on OTC Market in USA.Bayer Aktiengesellschaft (BAYRY) is traded on OTC Market in USA. It is located in Kaiser-Wilhelm-Allee 1 and employs 124,055 people.

Bayer Aktiengesellschaft Leadership Team

Jennifer Brendelto, Vice President - Communications of the Consumer Health Division
Heike Hausfeld, Member of the Supervisory Board
Peter Hausmann, Member of the Supervisory Board
Heiko Schipper, Member of the Management Board, Head of the Consumer Health Division
Thomas Fischer, Member of the Supervisory Board
Marijn Dekkers, Chairman of Management Board and CEO
Detlef Rennings, Member of the Supervisory Board
Helmut Panke, Member of the Supervisory Board
Werner Wenning, Chairman of the Supervisory Board
Reiner Hoffmann, Member of the Supervisory Board
Sue Rataj, Member of the Supervisory Board
Petra ReinboldKnape, Member of the Supervisory Board
Dieter Weinand, Member of the Management Board and Head of the Pharmaceuticals Division, North America Region
Werner Baumann, Chief Strategy and Portfolio Officer and Member of Management Board
Kemal Malik, Member of Management Board, Chief Medical Officer of Bayer Healthcare and Head of Global Devel. - Bayer Healthcare
Petra Kronen, Member of the Supervisory Board
Oliver Zuehlke, Member of the Supervisory Board
Thomas Elsner, Member of the Supervisory Board
Alexander Rosar, Head of Investor Relations
Simone BagelTrah, Member of the Supervisory Board
Michael SchmidtKiessling, Member of the Supervisory Board
ErnstLudwig Winnacker, Member of the Supervisory Board
Colleen Goggins, Member of the Supervisory Board
Heinz Webers, Member of the Supervisory Board
Johanna Faber, Member of the Supervisory Board
Paul Achleitner, Member of the Supervisory Board
Klaus Sturany, Independent Member of the Supervisory Board
Frank Loellgen, Member of the Supervisory Board
Andre Broich, Member of the Supervisory Board
Liam Condon, Member of Management Board and CEO of Bayer Cropscience
Patrick Thomas, CEO, Bayer MaterialScience
Yueksel Karaaslan, Member of the Supervisory Board
Thomas Ebeling, Member of the Supervisory Board
Erica Mann, Member of the Management Board, Head of the Consumer Health Division
Norbert Bischofberger, Member of the Supervisory Board
Johannes Dietsch, CFO and Member of Management Board
Hartmut Klusik, Member of the Management Board, Director of Human Resources, Technology & Sustainability
Michael Koenig, Member of the Management Board responsible for Human Resources
Clemens Boersig, Member of the Supervisory Board
Juergen Beunink, Interim Head of Investor Relations
Thomas Win, Vice Chairman of the Supervisory Board
Otmar Wiestler, Member of the Supervisory Board
Sabine Schaab, Member of the Supervisory Board
Wolfgang Plischke, Member of the Supervisory Board

Stock Performance Indicators

Did you try this?

Run Portfolio Reporting Now

   

Portfolio Reporting

Create custom reports across your portfolios and generate quick suggestion pitch
All  Next Launch Portfolio Reporting

Bayer Aktiengesellscha Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bayer Aktiengesellscha and Johnson Johnson. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Search macroaxis.com